The Nutshell

Daily News Roundup

Most Recent

Surprise, surprise. Sussex backs chemistry

By | May 15, 2006

Over the past few weeks, the leadership of the University of Sussex, in England, has faced a barrage of criticism from scientists, media and linkurl:politicians; over plans to linkurl:reshape its chemistry department; in favor of biological chemistry. The planned restructuring, widely seen as the brainchild of vice chancellor Alasdair Smith, was denigrated by a Nobel Laureate, protested against by st


Hwang charged with fraud, embezzlement

By | May 12, 2006

Hwang Woo-suk, the South Korean researcher who admitted fabricating data on human stem cell lines, has been charged with criminal fraud and embezzlement, and now potentially faces years in jail, prosecutors announced Friday (May 12). In a linkurl:statement;;_ylt=AoWnlxWJZt1f3kSQ6kx3JgoPLBIF;_ylu=X3oDMTA5aHJvMDdwBHNlYwN5bmNhdA-- provided to Reuters, prosecutor Lee In-kyu accused Hwang of being the lead actor in an elaborate plot to fabric


Histones are everywhere

By | May 11, 2006

Just the other day I was talking to a researcher on the phone whose work had unexpectedly intersected with nucleosome remodeling. I get the feeling it?s not an uncommon occurrence. I?ve enjoyed following the linkurl:explosion of research; on this topic in the past decade, in part because the analogies are irresistible. As the now pat intro to numerous papers on the subject says, with the sequence of the human genome at hand, scientists are lo


A word about BioMedCentral

By | May 1, 2006

Some of you may be wondering why The Scientist is today publishing a linkurl:news story; that on the face of it seems quite critical of BioMedCentral, our sister company. It's a fair question, and one with a simple answer: We are commited to covering significant developments, in science publishing and elsewhere, that are likely to be of interest to our readers, irrespective of the source of the story. This particular article is a test of the edit


A genome center on a chip?

By | April 25, 2006

A nifty paper in yesterday's online edition of PNAS could presage the future of microfluidics development -- not to mention of sequencing technology. linkurl:Richard Mathies; of the University of California, Berkeley, and colleagues linkurl:report; the development of an integrated chip capable of performing the complete Sanger sequencing protocol, from template to gel. Lab-on-a-chip, o


Goodbye, science writing mentor

By | April 25, 2006

I didn't know Laura van Dam particularly well, but I did have the chance to work with her. In 1993, while I was in college, I was an intern at Technology Review, where she was a senior editor. It was a good experience for me, thanks in no small part to Laura, who always had time for this unpolished kid who seemed to always be running off to the lab to finish my thesis. She was infinitely patient, particularly with the pieces that didn't make it into the magazine. I probably learned more when she

1 Comment

Petition backs animal research

By | April 21, 2006

In the UK, the battle for people's hearts and minds over animal research continues apace. For a long time, opponents of animal research dominated the news but linkurl:these days;, the tables seem to have turned. The latest thrust came yesterday when the Coalition for Medical Progress launched an linkurl:online petition; for those who see experiments on animals as being essential. As I write, after midnight


Chips spark surge in epigenetics

By | April 20, 2006

Since my colleague Brendan Maher returned from a chromatin meeting in January, it seems there's been a burst of activity in the epigenetics field, much of it covered here in __The Scientist__. On March 17, for instance, I linkurl:reported; on the publication of three papers in __Genes & Development__, which mapped the binding of the Dosage Compensation Complex (DCC) across the __Drosophila__ X chromosome during fly development. Today, __linkurl:Na


Clinical diagnostics in a Starbucks package

By | April 13, 2006

The __New York Times__ linkurl:has an interesting business story; on the growth of high-priced clinical diagnostic tests involving genomic and proteomic technologies. One chief scientific officer praised the makers of Oncotype DX (which rates the risk of breast cancer recurrence based on a panel of 12 genes) for validating their product in the clinic and then placing it ?in a Starbucks package at a high price.? At $3500 a pop, the test


Bill Clinton wants corn

By | April 12, 2006

The mood at linkurl:BIO yesterday; preceding Bill Clinton's speech felt more like a rock concert than a keynote address. In fact, I was very nearly carried away in a stampede when the conference organizers finally opened the barriers to the hall. When everyone finally got settled in, there was rapt attention during Clinton's 45-minute speech. True to form, he spoke with perfect organization, seamlessly citing statistics and facts without ever looking at notes. His theme for t


Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
The Scientist
The Scientist